Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

Expert-Backed Tips For Regowing Your Hair This article was reviewed by Knox Beasley, MD. Ask the internet how to get thicker ...

Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a ...

The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of ...

Among 27 men who received 25 mL to 1.5 L of a water-like liquid known as perfluorodecalin, 20 were able to retain it within ...

Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.

Tylah Tully looks at Vertex Minerals and its growing high-grade gold production in the latest episode of Stockhead's Who’s ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago period. The consensus estimate for Vertex ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...